Paula Cox‐North, Kelsey L. Hawkins, Sean T. Rossiter, Marie N. Hawley, Renuka Bhattacharya, Charles S. Landis – 18 April 2017 – Sofosbuvir (SOF) is a nonstructural 5B polymerase inhibitor with activity in all hepatitis C virus (HCV) genotypes and is the backbone of many anti‐HCV drug regimens. SOF is converted into inactive metabolites that undergo renal excretion.
Po‐Da Chen, Yao‐Ming Wu – 13 April 2017
Bruno Sangro, Diego Martínez‐Urbistondo, Lourens Bester, Jose I. Bilbao, Douglas M. Coldwell, Patrick Flamen, Andrew Kennedy, Jens Ricke, Ricky A. Sharma – 13 April 2017 – Selective internal radiation therapy (or radioembolization) by intra‐arterial injection of radioactive yttrium‐90‐loaded microspheres is increasingly used for the treatment of patients with liver metastases or primary liver cancer. The high‐dose beta‐radiation penetrates an average of only 2.5 mm from the source, thus limiting its effects to the site of delivery.
Paolo Magistri, Giuseppe Tarantino, Roberto Ballarin, Andrea Coratti, Fabrizio Di Benedetto – 13 April 2017
Zhenhuan Cao, Yali Liu, Lina Ma, Junfeng Lu, Yi Jin, Shan Ren, Zhimin He, Chengli Shen, Xinyue Chen – 13 April 2017 – Hepatitis B surface antigen (HBsAg) clearance represents a clinical cure, although the clearance rate is extremely low. The aim of this study was to evaluate the feasibility and safety profiles of pegylated‐interferon α‐2a (PEG‐IFNα‐2a) as a therapeutic option for inactive HBsAg carriers. There were 144 inactive HBsAg carriers enrolled and divided into a therapeutic group (102 subjects) and a control group (42 subjects).
Yongfeng Song, Chune Liu, Xia Liu, Jocelyn Trottier, Michele Beaudoin, Li Zhang, Chad Pope, Guangyong Peng, Olivier Barbier, Xiaobo Zhong, Linheng Li, Li Wang – 13 April 2017 – Based on our recent finding that disruption of bile acid (BA) homeostasis in mice results in the induction of hepatic long noncoding RNA H19 expression, we sought to elucidate the role of H19 in cholestatic liver fibrosis.
Hongqun Liu, Saumya Jayakumar, Mouhieddin Traboulsi, Samuel S. Lee – 13 April 2017 – The majority of patients on a waiting list for liver transplantation have end‐stage liver disease. Because of the marked peripheral vasodilatation of end‐stage cirrhosis that masks a latent myocardial dysfunction, cardiac abnormalities in the resting state are usually subclinical and escape the attention of physicians. However, when challenged, the systolic and diastolic contractile responses are attenuated.
Frank Kuo, Jonathan Park, Alice Chen – 13 April 2017
Xuan Guo, Shu Wang, Zhi‐Gang Qiu, Ya‐Ling Dou, Wei‐Li Liu, Dong Yang, Zhi‐Qiang Shen, Zhao‐Li Chen, Jing‐Feng Wang, Bin Zhang, Xin‐Wei Wang, Xiang‐Fei Guo, Xue‐Lian Zhang, Min Jin, Jun‐Wen Li – 13 April 2017 – The development of pathogenic mechanisms, specific antiviral treatments and preventive vaccines for hepatitis C virus (HCV) infection has been limited due to lack of cell culture models that can naturally imitate the entire HCV life cycle.
Hiroaki Haga, Irene K. Yan, David A. Borrelli, Akiko Matsuda, Mansi Parasramka, Neha Shukla, David D. Lee, Tushar Patel – 13 April 2017 – Hepatic ischemia/reperfusion injury (IRI) and associated inflammation contributes to liver dysfunction and complications after liver surgery and transplantation. Mesenchymal stem cells (MSCs) have been reported to reduce hepatic IRI because of their reparative immunomodulatory effects in injured tissues. Recent studies have highlighted beneficial effects of extracellular vesicles from mesenchymal stem cells (MSC‐EV) on tissue injury.